Although its selectivity is not necessarily superior to existing inhibitors, DLK1 competes with MSTN for binding to ActRIIB and promotes muscle regeneration through modulation of SMAD2/3 and Notch signaling pathways.[88] However, to date, no clinical trials have investigated DLK1 activation or overexpression as a strategy to promote muscle growth, although such studies may offer promising therapeutic opportunities for the management of metabolic disorders
That simplicity is not a minor convenienceit is a clinically meaningful improvement that ensures patients actually adhere to their medication
It produces a single number that places you somewhere on a scale from underweight to severely obese, and that number has become the primary gatekeeper for GLP-1 medication access
Diabetes, metabolic syndrome and obesity: targets and therapy, 10, 403412.
No brand-name GLP-1 access
It should not be shared with others